Search tips
Search criteria 


Logo of bloodtransLink to Publisher's site
Blood Transfus. 2012 July; 10(3): 257–259.
PMCID: PMC3417722

Utility of testing for factor V Leiden

In 1993, Dahlback and colleagues reported that a poor anticoagulant response to activated protein C was associated with the risk of thrombosis1. Subsequently, it appeared clear that the so-called activated protein C resistance is mostly caused by a mutation in the Arg506 cleavage site of activated factor V26. As a consequence, the activated mutant factor V molecule, commonly called factor V Leiden (FVL), is resistant to proteolytic inactivation by activated protein C and retains its procoagulant activity2. FVL mutation is inherited as an autosomal dominant trait and it is the most prevalent venous thrombotic risk factor in the Caucasian population, being present in 3–7% of individuals, but is rare in Asians and Africans710. Other less common inherited coagulation abnormalities include deficiencies of protein S and protein C, prothrombin G20210A mutation, and elevated levels of clotting factor VIII11.

Heterozygous carriers of FVL have an approximately 3- to 5-fold increased risk of venous thromboembolism (VTE), whereas the risk in homozygous carriers is estimated to be increased 80 times3. The absolute incidence of VTE in patients with FVL mutation ranges from 0.19% per year to 0.45% per year, compared to 0.10% per year in individuals without the mutation11. Vice versa, FVL is present in the heterozygous form in approximately 15–20% of VTE patients9. However, not all mutation carriers develop VTE and their absolute thrombotic risk will depend on the interaction between the FVL and other inherited thrombophilic mutations or acquired high-risk situations, such as age, pregnancy, immobilisation, prolonged travel, major or orthopaedic surgery, cancer, use of oral contraceptives and hormone replacement therapy3. For instance, the risk of VTE in a young woman with FVL with no family history of VTE is low, approximately 6/10,000 per year, but if this woman takes oral contraceptives, her risk increases 5-fold. Similar estimates can be made for FVL carriers who take hormone replacement therapy or who are pregnant12. In addition, FVL increases the risk of recurrent foetal loss, possibly due to placental thrombosis, and has also been associated with increased risk of severe pre-eclampsia, placental abruption, unexplained intrauterine foetal growth retardation, and stillbirth1316.

The risk of recurrent VTE in carriers of FVL is less clear, as a number of prospective cohort studies have addressed this question, but with conflicting results17,18. However, a meta-analysis of ten pooled studies found that heterozygosity for FVL was associated with a 1.4-fold increased risk of recurrent VTE compared with the risk in people without this mutation19.

Thus, according to the American College of Medical Genetics20, testing for FV Leiden should be performed in the following circumstances: first VTE before 50 years of age, first VTE over 50 years of age in the absence of malignancy, venous thrombosis in unusual sites (such as hepatic, mesenteric and cerebral veins), recurrent VTE, first VTE and a strong family history of VTE, VTE during pregnancy, in the post-partum period or in women taking oral contraceptives or under hormone replacement therapy, women with unexplained pregnancy loss and asymptomatic adult family members of relatives with documented FVL. Indeed, identifying FV Leiden in the latter cases is very helpful as such individuals may benefit from targeted thromboprophylaxis in high-risk situations (e.g., pregnancy, puerperium, surgery, immobilisation and trauma), and the avoidance of acquired risk factors, most notably oral contraceptives. By contrast, FVL is not recommended as a general screening test, as a routine initial test during pregnancy, before use of oral contraceptives or hormone replacement therapy, or as a routine initial test in patients with arterial thrombosis21. In addition, given that FVL-associated thrombophilia is an adult-onset disorder with low penetrance, foetal testing and routine screening of neonates are not indicated.

Finally, another interesting field of potential application of FVL testing is the selection of blood donors22. A number of studies analysed the prevalence of this mutation in blood donors and found a distribution similar to that in the general population23,24, although in some cases a high prevalence of FVL carriers was detected25. However, considering the epidemiology of FVL in blood donors, the knowledge of their FVL status could be useful as it might influence their suitability for blood donation. Indeed, heterozygous FVL subjects are allowed to donate whole blood or by apheresis without any restriction, unless they are currently symptomatic or under antithrombotic therapy. Vice versa, individuals homozygous for FVL or with double heterozygosity for FVL and another inherited thrombophilic risk factor and a positive history of VTE should not donate whole blood or apheresis, while those with no history of VTE are allowed to donate whole blood (with elimination of the plasma component) but not by apheresis26. This practice is also aimed to safeguard the health of the blood donors as there are a few case reports describing thrombotic complications in donors with associated thrombophilia following apheresis donation, due to activation of the coagulation system caused by contact between the blood and artificial surfaces27,28. Table I summarises the utility of FVL testing.

Table I
Indications for factor V Leiden testing.

In conclusion, the discovery of FVL has represented a great advance in the understanding of the molecular mechanisms leading to VTE. However, diagnostic thrombophilic work-up, including FVL testing, should be tailored on individual patient’s characteristics. Thus, when used appropriately, FVL testing can have a positive impact on the health care of the people tested and their family members.


The Author declares no conflicts of interest.


1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004–8. [PubMed]
2. Nicolaes GAF, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol. 2002;22:530–8. [PubMed]
3. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;43:249–90. [PubMed]
4. Franchini M, Lippi G. Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage? Semin Thromb Hemost. 2011;37:275–9. [PubMed]
5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–7. [PubMed]
6. Voorberg J, Roese J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V. Lancet. 1994;343:1535–6. [PubMed]
7. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277:1305–7. [PubMed]
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133–4. [PubMed]
9. Rees DC. The population genetics of factor V Leiden. Br J Haematol. 1996;95:579–86. [PubMed]
10. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397–402. [PubMed]
11. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7(Suppl. 1):301–4. [PubMed]
12. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost. 2007;33:573–81. [PubMed]
13. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998;128:1000–3. [PubMed]
14. Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost. 1999;82:634–40. [PubMed]
15. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9–13. [PubMed]
16. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996;175:902–5. [PubMed]
17. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 –> Gln mutation in the gene for factor V (factor V Leiden) N Engl J Med. 1997;336:399–403. [PubMed]
18. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624–8. [PubMed]
19. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166:729–36. [PubMed]
20. Grody WW, Griffin JH, Taylor AK, et al. ACMG Factor V. Leiden Working Group American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139–48. [PMC free article] [PubMed]
21. Whitlatch NL, Ortel TL. Thrombophilias: when should we test and how does it help? Semin Respir Crit Care. 2008;29:25–39. [PubMed]
22. Gessoni G, Valverde S, Canistro R, Manoni F. GeneXpert in the diagnosis of risk factors for thrombophilia: evaluation of its use in a small laboratory. Blood Transfus. 2012;10:228–9. [PMC free article] [PubMed]
23. Maalej L, Hadjkacem B, Ben Amor I, et al. Prevalence of factor V Leiden in south Tunisian blood donors. J Thromb Thrombolysis. 2011;32:116–9. [PubMed]
24. Antoniadi T, Hatzis T, Kroupis C, et al. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol. 1999;61:265–7. [PubMed]
25. Gessoni G, Valverde S, Canistro R, Manoni F. Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population. Blood Transfus. 2010;8:193–5. [PMC free article] [PubMed]
26. Consulta Tecnica Permanenet per il Sistema Trasfusionale Regionale. Protocollo per la selezione del donatore di sangue ed emocomponenti. Regione Emilia-Romagna 1 ottobre 2009. Available at: Accessed on: 10 May 2012.
27. Ovali E, Ratip S, Ozmenoglu M, et al. Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis. Transfus Apher Sci. 2003;28:201–6. [PubMed]
28. Zimmermann B, Scheel H, Wegner H. Thrombophilia in blood-donation for plasma- and cytapheresis caused by antithrombin III depletion. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115:314–8. [PubMed]

Articles from Blood Transfusion are provided here courtesy of SIMTI Servizi